Equity (Details) $ / shares in Units, $ in Thousands, vaccine_dose in Millions, shares in Millions	Mar. 18, 2021 USD ($) vaccine_dose	Jun. 30, 2024 USD ($) $ / shares	Dec. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Mar. 01, 2021 $ / shares shares
Subsidiary, Sale of Stock [Line Items]
Convertible preferred stock, par value (in USD per share) | $ / shares		$ 0.01	$ 0.01
Preferred stock issued | $		$ 0	$ 1		$ 5,000
Preferred stock, outstanding | $				$ 4,100
Fair Value, Inputs, Level 3 | Discount Rate
Subsidiary, Sale of Stock [Line Items]
Preferred stock, measurement input					0.15
COVAXIN Preferred Stock Purchase Agreement
Subsidiary, Sale of Stock [Line Items]
Agreement to sell, number of shares issued in transaction (in shares) | shares						0.1
Convertible preferred stock, par value (in USD per share) | $ / shares						$ 0.01
Agreement to sell, price per share (in USD per share) | $ / shares						$ 109.60
Advance payment amount | $	$ 6,000
Conversion ratio (in shares)						10
Supply agreement, number of doses | vaccine_dose	10.0